Payment overview · 2025
General Payments
$322.41
16 reported records · 9 companies
Healthcare provider profile · identity verified
Brian O'Leary, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NAPERVILLE, IL · NPI 1295702439
Verified facts
What the public records show
CMS Open Payments records show Brian O'Leary, MD received $322.41 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.16 | 21.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.73 | 18.8% | 3 | 2025 |
| Sanara MedTech Inc. | Unresolved — no canonical attribution shown | $58.24 | 18.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.38 | 13.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.82 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.12 | 5.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.62 | 5.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.39 | 5.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.95 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $322.41 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.16 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.16 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $63.78 | 3 | 2025 |
Source payment records
|
|||||
| CellerateRX Normalized: celleraterx |
Device | Sanara MedTech Inc. | $58.24 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.38 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 95 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 376 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 91 |
| Losartan Potassium | Losartan Potassium | 315 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 93 |
| Duloxetine Hcl | Duloxetine Hcl | 236 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 71 |
| Gabapentin | Gabapentin | 222 | 59 |
| Lisinopril | Lisinopril | 214 | 65 |
| Metformin Hcl | Metformin Hcl | 213 | 54 |
| Carvedilol | Carvedilol | 185 | 50 |
| Omeprazole | Omeprazole | 179 | 65 |
| Furosemide | Furosemide | 165 | 63 |
| Metformin Hcl Er | Metformin Hcl | 131 | 40 |
| Montelukast Sodium | Montelukast Sodium | 123 | 41 |
| Trazodone Hcl | Trazodone Hcl | 120 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 34 |
| Tramadol Hcl | Tramadol Hcl | 117 | 44 |
| Allopurinol | Allopurinol | 116 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 38 |
| Alprazolam | Alprazolam | 109 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 20 |
| Prednisone | Prednisone | 97 | 44 |
| Potassium Chloride | Potassium Chloride | 96 | 35 |
| Eliquis | Apixaban | 95 | 30 |
| Jardiance | Empagliflozin | 95 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 24 |
| Ezetimibe | Ezetimibe | 81 | 27 |
| Simvastatin | Simvastatin | 81 | 23 |
| Famotidine | Famotidine | 80 | 25 |
| Ozempic | Semaglutide | 80 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 42 |
| Mounjaro | Tirzepatide | 78 | 17 |
| Sertraline Hcl | Sertraline Hcl | 70 | 20 |
| Memantine Hcl | Memantine Hcl | 69 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 33 |
| Pregabalin | Pregabalin | 61 | 21 |
| Spironolactone | Spironolactone | 61 | 19 |
| Valsartan | Valsartan | 61 | 21 |
| Mirtazapine | Mirtazapine | 58 | 21 |
| Nystatin | Nystatin | 57 | 26 |
| Warfarin Sodium | Warfarin Sodium | 55 | 11 |
| Azithromycin | Azithromycin | 54 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 17 |
| Torsemide | Torsemide | 54 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Celecoxib | Celecoxib | 51 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Nifedipine Er | Nifedipine | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Baclofen | Baclofen | 47 | 16 |
| Meloxicam | Meloxicam | 47 | 19 |
| Lorazepam | Lorazepam | 45 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 11 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 14 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Irbesartan | Irbesartan | 38 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 38 | 13 |
| Ondansetron Odt | Ondansetron | 38 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 36 | 12 |
| Diazepam | Diazepam | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 26 |
| Bumetanide | Bumetanide | 31 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 12 |
| Topiramate | Topiramate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 22 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 28 | 11 |
| Tolvaptan | Tolvaptan | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 15 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 13 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 19 |
| Cephalexin | Cephalexin | 21 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Linzess | Linaclotide | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Cefadroxil | Cefadroxil | 15 | 15 |
| Estradiol | Estradiol | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $322.41 · 16 records | Novo Nordisk Inc | CAPVAXIVE, CellerateRX, ELIQUIS, GARDASIL 9, GEMTESA, JARDIANCE, MOUNJARO, Ozempic, REXULTI, Rybelsus, VAXNEUVANCE, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error